Remsima Stars In Orion Pharma’s First Half
Executive Summary
Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.
You may also be interested in...
J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
The pharma is confident in its current discounting to protect Remicade market share in the US – it still plans to focus on a strategy involving bundling and relying on brand loyalty.
J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
The pharma is confident in its current discounting to protect Remicade market share in the US – it still plans to focus on a strategy involving bundling and relying on brand loyalty.
Biosimilars A Driving Force Behind Korean Pharma Exports
Remsima/Inflectra's rapid penetration into global biosimilar markets is helping Celltrion to grow into a global biologics powerhouse and also boosting South Korea's pharma exports. The country has logged a biologics trade surplus for the first time in years, due mainly to a surge in exports of biosimilar infliximab, and trend only set to continue with more approvals and launches on the horizon.